TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...

Descripció completa

Dades bibliogràfiques
Autors principals:	E N Aleksandrova, E Yu Panasyuk, A S Avdeyeva, A A Novikov, G V Lukina, M V Cherkasova, N V Klimova, E L Nasonov
Format:	Article
Idioma:	Russian
Publicat:	IMA PRESS LLC 2011-06-01
Col·lecció:	Научно-практическая ревматология
Matèries:	rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies
Accés en línia:	https://rsp.mediar-press.net/rsp/article/view/705

Ítems similars

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
per: Anastasia Sergeyevna Avdeyeva, et al.
Publicat: (2012-06-01)

Bone destruction in rheumatoid arthritis: role of autoantibodies
per: Anastasia Sergeyevna Avdeyeva, et al.
Publicat: (2013-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
per: Elena Nikolayevna Aleksandrova, et al.
Publicat: (2012-02-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
per: Maria Sergeevna Voronina, et al.
Publicat: (2012-10-01)

Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
per: Somayye Norouzi, et al.
Publicat: (2020-08-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
per: Evgeniy L'vovich Nasonov, et al.
Publicat: (2010-05-01)

Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity
per: Tulus Widiyanto, et al.
Publicat: (2022-08-01)

Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis
per: Natal'ya Petrovna Shilkina, et al.
Publicat: (2011-05-01)

Serum sirtuin-1 a potential marker in the diagnosis of rheumatoid arthritis
per: Liming Tan, et al.
Publicat: (2023-12-01)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
per: Nicole H. Trier, et al.
Publicat: (2019-06-01)

Assessment of the Correlation between Disease Activity and Serum Biomarker Anti-MCV and IL6 in Iraqi Patients with Rheumatoid Arthritis
per: Dania A. Ali, et al.
Publicat: (2024-10-01)

Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
per: N. V. Bunchuk
Publicat: (2023-01-01)

Antibodies to cyclic citrullinized peptide in rheumatoid arthritis
per: E N Aleksandrova, et al.
Publicat: (2004-12-01)

Epitope Specificity of Anti-Citrullinated Protein Antibodies
per: Nicole H. Trier, et al.
Publicat: (2017-03-01)

Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis
per: Akio Umemoto, et al.
Publicat: (2023-02-01)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
per: Hui-Chun Yu, et al.
Publicat: (2019-01-01)

Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Function of Epitope Structure and Composition
per: Ilaria Fanelli, et al.
Publicat: (2021-07-01)

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study
per: Pit Hui Lew, et al.
Publicat: (2021-07-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
per: A. S. Avdeeva, et al.
Publicat: (2022-05-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
per: E. L. Nasonov, et al.
Publicat: (2018-01-01)

Tocilizumab (Actemra)
per: Martin Sheppard, et al.
Publicat: (2017-09-01)

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
per: Hisakata Yamada, et al.
Publicat: (2020-04-01)

Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis in comparison with other rheumatic diseases; a nephrology point of view
per: Alireza Sadeghi, et al.
Publicat: (2017-04-01)

Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels
per: Diana Castillo-Martínez, et al.
Publicat: (2017-02-01)

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement
per: S.L.E. Ribeiro, et al.
Publicat: (2008-11-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
per: V. V. Badokin, et al.
Publicat: (2011-06-01)

When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis
per: Marino Paroli, et al.
Publicat: (2023-10-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis
per: Damjanovska Ljubinka, et al.
Publicat: (2007-01-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
per: I. A. Guseva, et al.
Publicat: (2016-03-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
per: E. L. Nasonov
Publicat: (2017-04-01)

The clinical aspect of overweight on rheumatoid arthritis and disease activity
per: Haitham Ahmed, et al.
Publicat: (2019-06-01)

Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis
per: Lakshmi Deepika Yarlagadda, et al.
Publicat: (2020-01-01)

Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis
per: Alessandra Zaccardelli, et al.
Publicat: (2019-11-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
per: N. V. Rebrova, et al.
Publicat: (2022-07-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
per: E Yu Panasyuk, et al.
Publicat: (2011-08-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
per: S O Salugina, et al.
Publicat: (2009-06-01)

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
per: Noriyoshi Ogawa, et al.
Publicat: (2019-01-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis
per: Mehanović-Nikolić Jasminka, et al.
Publicat: (2008-01-01)

An assessment of anti-citrullinated protein antibody in systemically healthy individuals with or without chronic periodontitis: A case–control study
per: Ankita Rajaram Yadav, et al.
Publicat: (2020-01-01)

DIAGNOSTIC VALUE OF ANTI-PEPTIDYLARGININE DEIMINASE TYPE 4 (PADI-4) AND ANTI- CITRULLINATED PEPTIDE ANTIBODIES (ACCP) IN IRAQI PATIENTS WITH RHEUMATOID ARTHRITIS
per: Hassan J Hasony, et al.
Publicat: (2014-06-01)